Touchlight Genetics Ltd
Morelands & Riverdale Buildings
Lower Sunbury Road
About Touchlight Genetics LtdTouchlight was established on the conviction that our ever increasing understanding of DNA would lead to its emergence as a material of the future.
As such we have developed, patented, scaled and evidenced a revolutionary platform to enable the next generation of DNA industries.
CEO: Johnny Ohlson
7 articles about Touchlight Genetics Ltd
Touchlight Completes Expansion, Creating One of the World’s Largest DNA Manufacturing Facilities in London, UK
Facility will have capacity that exceeds global plasmid DNA demand and can enable commercialisation of genetic medicines.
Touchlight, a CDMO pioneering enzymatic DNA production to enable genetic medicines, today announced the first FDA clearance of an Investigational New Drug (IND) application in the US utilising doggybone DNA (dbDNA™).
FDA Accepts Drug Master File, Signifying a New Milestone for Touchlight’s Enzymatic doggybone DNA Technology
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, today announced a ground-breaking new milestone for its enzymatic doggybone DNA (dbDNA™), following the FDA acceptance of the Drug Master File (DMF) for GMP grade dbDNA.
Touchlight and Odimma Therapeutics Announce Clinical Material Supply Agreement to Develop Personalised Cancer Therapy Utilising Doggybone DNA
Touchlight announces a development and supply agreement with Odimma Therapeutics, a French biotech company focusing on personalised cancer immunotherapy.
Asklepios BioPharmaceutical, Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, and Touchlight, a biotechnology company pioneering enzymatic DNA production, have announced a revised structure to their former joint venture, Touchlight AAV.
Touchlight and Vanderbilt University Medical Center collaborate on DARPA Pandemic Prevention Platform programme to develop synthetic DNA-based antibody to protect against emerging threats
Touchlight, the leading synthetic DNA manufacturer, is collaborating with the Vanderbilt Vaccine Center at Vanderbilt University Medical Center as part of the DARPA P3 programme.